EP
ACHV icon

Essential Partners’s Achieve Life Sciences ACHV Stock Holding History

Essential Partners’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29
Closed -$66 – 2669
2025
Q2 		$66 Buy
+29
New +$83 ﹤0.01% 2119

Other funds holding ACHV

PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Essential Partners's ACHV Position: Q3 2025 in Review

Essential Partners sold out of Achieve Life Sciences (ACHV) in Q3 2025, closing a stake of 29 shares — an estimated $66 sold.

Essential Partners first reported a position in ACHV in Q2 2025 and held it in 1 quarter. The position peaked at $66 in Q2 2025. 66 funds tracked by Wall St. Rank hold ACHV as of Q3 2025.

  • Essential Partners reported no remaining Achieve Life Sciences position as of Q3 2025 after selling out during the quarter.
  • Essential Partners sold 29 Achieve Life Sciences shares in Q3 2025, an estimated $66.
  • Essential Partners first reported a position in Achieve Life Sciences in Q2 2025 and held it in 1 quarter.
  • Essential Partners's Achieve Life Sciences position peaked at $66 in Q2 2025.
  • 66 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.